Idec Zevalin Clears Cmte.: Non-Refractory Use May Be Accelerated Approval

FDA should consider approving Idec's Zevalin for use in lymphoma patients who have not failed Rituxan therapy under the accelerated approval regulations, FDA's Oncologic Drugs Advisory Committee said Sept. 11.